27 min listen
Navigating Future Challenges in Lymphoma
FromThe Hematologist
ratings:
Length:
17 minutes
Released:
May 6, 2015
Format:
Podcast episode
Description
The strategic roadmap developed at the original ASH Meeting on Lymphoma Biology held in August 2014 was recently published in Blood. To continue this important conversation, Dr. Ann LaCasce (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA) and Dr. David Weinstock (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA) have contributed a companion article, just published in the May/June issue of The Hematologist. This podcast features additional insight from the authors, with The Hematologist Editor-in-Chief Dr. Jason Gotlib (Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA) moderating the discussion. Read the article here: http://www.hematology.org/Thehematologist/Features/4003.aspx
Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/
Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/
Released:
May 6, 2015
Format:
Podcast episode
Titles in the series (100)
BCL-2 Is an Effective Target in Chronic Lymphocytic Leukemia: In her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or sm by The Hematologist